#aduhelm

Biogen Announces Discontinuation of Aduhelm: Key Points and Potential Implications

Biogen Announces Discontinuation of Aduhelm: Key Points and Potential Implications

Untangling the Plaque Mess in Neurological Disorders: “Oh, What a Tangled Web we Weave, When First…

In 1906, Alois Alzheimer first reported a connection between dementia and plaques after postmortem examination of the brain and medical…

Aduhelm: An Opportunity for Prescription Drug Reform

The FDA should approve more drugs faster, but we should stop forcing Medicare to pay for cost-ineffective drugs.

PBMs Use Evidence in Determining Aduhelm Coverage

Over the summer, when the U.S. Food and Drug Administration (FDA) approved the drug Aduhelm to treat Alzheimer’s Disease, I said that the…

Trust at Stake: Alzheimer’s Association’s role in FDA’s approval of Aduhelm

How Aduhelm, an Unproven Alzheimer’s Drug, Got Approved

Why does FDA’s Decision to Approve Alzheimer’s Drug impact vaccine rollout?

The FDA generally makes good evidence-based decisions. This is not always the case. Sometimes they will screw things up.

Thinking Citizen Blog — Aduhelm — Did the FDA Approve the Drug Too Soon?

Thinking Citizen Blog — Thursday is Health, Health Care, Health Insurance and Global Health Policy Day